Zynex (OTCMKTS: ZYXI) is one of 46 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare Zynex to related companies based on the strength of its analyst recommendations, earnings, risk, institutional ownership, profitability, dividends and valuation.
This table compares Zynex and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Zynex and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Zynex||$23.43 million||$7.36 million||15.68|
|Zynex Competitors||$1.10 billion||$121.87 million||-38.51|
Zynex’s rivals have higher revenue and earnings than Zynex. Zynex is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Zynex has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Zynex’s rivals have a beta of 1.57, meaning that their average share price is 57% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Zynex and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Electromedical equipment” companies have a potential upside of 16.50%. Given Zynex’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Zynex has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
0.0% of Zynex shares are held by institutional investors. Comparatively, 40.7% of shares of all “Electromedical equipment” companies are held by institutional investors. 20.2% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Zynex rivals beat Zynex on 9 of the 13 factors compared.
Zynex Company Profile
Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.